Document is current

Article History

Received: 28 January 2025

Accepted: 11 March 2025

First Online: 7 April 2025

Declarations

:

: Both studies were undertaken in accordance with the Declaration of Helsinki and were approved by central or site-specific review boards or ethics committees. All participants provided written informed consent.

: Not applicable.

: Data were partially previously presented as an oral presentation at IDWeek 2021 (virtual), September 29–October 3, and in poster format at IDWeek 2022, October 19–23, Washington, DC, USA.

: E.S.D. has received research support from Gilead Sciences, Inc. and ViiV Healthcare; and consultancy fees from Gilead Sciences, Inc., Genentech, and ViiV Healthcare. C.O. has received grants or contracts from ViiV Healthcare (paid to institution); speaker honoraria from Gilead Sciences, Inc., GSK, MSD, and ViiV Healthcare; and support for attending meetings and/or travel from Gilead Sciences, Inc.; and is a governing council member of the International AIDS Society (unpaid). P.E.S. has received research support from Gilead Sciences, Inc., and ViiV Healthcare; and consultancy fees from AbbVie, Gilead Sciences, Inc., Merck, and ViiV Healthcare. D.H. has no conflicts of interest to disclose. A.P. has received grants or contracts from Gilead Sciences, Inc., and ViiV Healthcare (paid to institution); payment or honoraria for lectures, presentations, or educational events from Gilead Sciences, Inc., and ViiV Healthcare; and support for attending meetings and/or travel from Gilead Sciences, Inc., and ViiV Healthcare; and is President of NEAT ID and a member of guideline committees for BHIVA and EACS. K.W. has received research support from Gilead Sciences, Inc. C.B. has received speaker honoraria from Gilead Sciences, Inc.; and support for attending meetings and/or travel from Gilead Sciences, Inc. J.M.T. has received grants or contracts from MSD; consulting fees and speaker honoraria from Gilead Sciences, Inc., Janssen, MSD, and ViiV Healthcare; and support for attending meetings and/or travel from Gilead Sciences, Inc., Janssen, and MSD; and has participated on a data safety monitoring board or advisory board for Gilead Sciences, Inc., Janssen, MSD, and ViiV Healthcare. H.L., C.D., C.C., S.M., and J.T.H. are employees of, and hold stock/stock options in, Gilead Sciences, Inc. M.R. has received consulting fees from AbbVie, Gilead Sciences, Inc., Merck, and ViiV Healthcare; and speaker honoraria from AbbVie, Gilead Sciences, Inc., and ViiV Healthcare.